KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Goodwill & Intangibles: 2009-2024

Historic Goodwill & Intangibles for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $451.5 million.

  • Biomarin Pharmaceutical's Goodwill & Intangibles fell 6.08% to $429.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.3 million, marking a year-over-year decrease of 6.08%. This contributed to the annual value of $451.5 million for FY2024, which is 8.03% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Goodwill & Intangibles stood at $451.5 million for FY2024, which was down 8.03% from $490.9 million recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Goodwill & Intangibles high stood at $613.5 million for FY2020, and its period low was $451.5 million during FY2024.
  • Over the past 3 years, Biomarin Pharmaceutical's median Goodwill & Intangibles value was $490.9 million (recorded in 2023), while the average stood at $492.4 million.
  • Data for Biomarin Pharmaceutical's Goodwill & Intangibles shows a maximum YoY dropped of 8.56% (in 2022) over the last 5 years.
  • Biomarin Pharmaceutical's Goodwill & Intangibles (Yearly) stood at $613.5 million in 2020, then dropped by 4.67% to $584.9 million in 2021, then declined by 8.56% to $534.8 million in 2022, then decreased by 8.20% to $490.9 million in 2023, then decreased by 8.03% to $451.5 million in 2024.